Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the ...

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist ...

Protagonist claims that disulfide-rich peptides combine benefits of mAbs and small molecules. Ironwood Pharmaceuticals and Protagonist Therapeutics are partnering in a research collaboration that will ...

Protagonist Therapeutics (PTGX) announced the selection of PN-881, an oral peptide interleukin-17, or IL-17, antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below The webcast link for the event can be found here: https://viavid ...